Filing nothing today — it's math, not reluctance. Book β0.9106 pinned on the 0.90 floor. Funded from SPY (β1.0), no add clears unless its beta is well north of 1.0. Live tests, all vetoed on the floor:

• CSCO 2.5%, SPY→64.2% → β0.898 (0.2bp under)
• CSCO 2.2% + deeper SPY trim → β0.887
• CSCO + UNP → β0.877

Off-the-highs quality fails the floor solo: MMC 0.752, ADP 0.841, AMGN 0.403, LMT 0.113, RTX 0.298, DE 0.897. Beta-≥1.0 names are rich/at highs: CAT 1.565 @43x, TXN 1.31 @49.8x — won't chase.

Two names print TODAY (freeze): HON (Margaret #23, the winner — 13.7x fwd, 4.1% yld/23% payout, β0.93, breakup catalyst) and UNP (my rail add). UNP also live $292.56, +9.4%/window, ~3.5% off high — double-disqualified.

Correction for the record: CSCO is NOT at its high — live $112.21, -3.7%/window, ~14% off the $129.88 high (EODHD summary was stale). Mid-range, reports 08-12 clear. Cleanest beta-additive quality name we have on price+fundamentals; only the floor math blocks it today.

Sequencing to unblock: seat HON next session post-print (count 15→16, cash-flow-today, β0.93 doesn't drag) — that rebuilds count and gives the beta average room; THEN CSCO clears. Don't breach the floor to rush it. Backing Margaret's no-forced-buy.

The box is a vise on my lane. Cash-flow-today + beta ≥0.90 + no-chasing-highs eliminates most of my bench: XOM 0.18, BMY 0.26, GILD 0.33, ADP 0.84, TJX 0.62, CMCSA 0.66 — all sub-0.90, DOA solo against the floor. The names that carry beta are either rich or reporting.

HON is the fundamental winner — thesis #23, conv 4. FY25 10-K (SEC XBRL, period-end 2025-12-31): rev $37.4B, op inc $8.13B (21.7% margin, UP YoY from $7.67B), OCF $6.41B, EPS $7.36, $12.5B cash. 4.1% fwd yield on a 23% payout — cash-flow-today, covered many times. Cheap-end: 13.7x fwd / 15.9x EV/EBITDA, ~10% off the $258.86 52w high ($232.99 last), above 50d/200d. Beta 0.93 CLEARS the floor. Mid three-way breakup catalyst. Ignore EODHD's -41.9% EPS-YoY — split/spin artifact; the filing shows op income rising.

Why not today: HON reports Q2 07-23 — today. Opening into the print trips the post-earnings sizing freeze and repeats the AAPL mistake we killed 4-0 on 07-20. TABLE for the NEXT session, post-print, ~2.5% from SPY — fixes count 15→16, adds cash-flow-today, funded from SPY, doesn't drag beta. STOP: op margin <17%, OCF <$5B, breakup delayed/cancelled, or -15% rel.

Rejected on discipline: TXN 49.8x/38.6x & ADI 56.8x — near highs, won't pay. CSCO beta 1.007 clean & reports 08-12 clear, but 23.6x fwd / 25x EV-EBITDA at its 52w high on AI-networking momentum — chasing the top. QUAL beta 0.90 sits ON the floor (basket drags to 0.9089) and near its own high — thin edge.

I'm not forcing a weak name into the count today. The floor is what's killing my value bench. Bring HON clean next session and it fixes count, cash, and the active gap in one motion. Daniel — flag HON for the next agenda, post-print.

Regime (Priya's, tighter): 10yr 4.63, reals 2.37 — 4th-week cycle high, refuses to ease. Duration cap ON: quality / low-vol / cash-flow-today. HY OAS 2.69 complacent, VIX 16.6 benign — low-vol tilt is cheap. WTI $70→$84 in two weeks: energy hedge vindicated, hold XOM.

The box (binds before we spend): cash 1.78% sub-floor; count 15 vs 18 min-holdings (2 under — must ADD names); beta 0.911 on the 0.90 floor (nothing added can pull it lower — kills solo low-beta adds and net closes).

Target gross ~98% — spend cash to floor-plus.

Sectors: SPY 65.2% is the albatross (-17.3bps active) — grind into active names, but every recycle must ADD a holding, not swap 1-for-1. Lean OUT of Financials adds — best sector since inception (+39.8bps active) but +6.3pp overweight bled -12.5bps LAST meeting (SPGI -13.3, V -9.4). Engine (V/GS/SPGI) stays; no new weight there. Close TMT (-8.3pp underweight, carries the beta we need). Watch Comm Svcs / GOOGL (-8.9 active).

Factor sponsored: quality + low-vol + cash-flow-today, energy intact.

Ask the room: bring 2+ new quality names, beta ≥0.90 each, funded from SPY — fixes count, cash, and the active gap in one motion. Solo low-beta adds are DOA vs the floor.

#90 — CME close + HD 2.5% open, one inseparable pair. AAPL as the recycle leg is done — voted down 4-0 (52w high, 40x, 07-30 print inside the freeze) and vetoed on a hard risk limit. HD is the strictly cleaner leg for the identical job.

Why CME goes: β0.26 dead money, -16bps active since inception (second-worst detractor behind SPY), no live thesis. Reports 07-22 inside the freeze — exit before the print. Solo close trips the 18-min-holdings floor at 13; paired with HD, count holds 14.

Why HD (2.5%): ~19% off the $418 52w high, between 50d/200d — trough of a rate-sensitive cyclical soft patch, not a franchise crack. FY25 (10-K, SEC XBRL): rev $164.7B, ~12.7% op margin, $16.3B OCF, 2.75% aristocrat. Full clip vs AAPL's 2.3% fresh-high starter. Earnings 08-18, clear of freeze.

GATE (live basket, zero breaches): β0.9101→0.9039 (holds 0.90 floor), cash 1.74→4.09%, Cons Disc 7.4→9.6% (closes worst active underweight), Financials 19.7→17.0%, count 14, top-5 76.1%.

STOP (HD): comps structurally negative, op margin <11%, OCF <$13B, or -15% rel. Catalyst: CME's 07-22 print — we exit ahead of it. To the vote.

#86 AAPL 2.3% open — tabled, not filed. It's a valid CME-recycle partner and clears the gate zero breaches (β0.9101→0.9055, cash→4.09%, closes most of the -7.5pp TMT underweight, count holds 14). But AAPL last close $333.74 is at the $334.99 52w high, +12.6% in a month, 40x trailing / 35x fwd, into a 07-30 print 10 days out. That's chasing the top into an event. On 07-16 I sized AAPL 2.3% for exactly this caveat — ten days later it's higher and closer to the catalyst. I won't open it here.

Re-filing the swap the room already voted 4-0: CME close + HD 2.5%, one inseparable pair. The min-holdings veto (13 vs 18) killed CME's close, not the swap logic — pairing one-for-one holds the count at 14. HD is the strictly cleaner leg for the identical job: ~19% off its high, trough of a rate-sensitive cyclical soft patch, reports 08-18 clear of the freeze. Basket clears zero breaches: β0.9101→0.9039 (holds 0.90 floor), cash 1.74→4.09%, Cons Disc 7.4→9.6% (closes the worst active-bleeding underweight), Financials 19.7→17.0%, top-5 76.1%.

STOP (HD): comps structurally negative, op margin <11%, OCF <$13B, or -15% rel. Catalyst now: CME's 07-22 print — we exit ahead of it. To the vote.

Filing CME full close + HD 2.5% open as one inseparable pair. Theses #22 (CME retire) + #21 (HD).

This is the recycle I've owed since 06-18. It kept getting blocked because closing CME solo drops us to 13 vs the 18-name min-holdings floor. Pairing it one-for-one with HD fixes that: CME out, HD in, count holds at 14, no floor trip. And CME reports 07-22 — I want out before the print, not resizing into it under the freeze. Today is the window.

GATE (live check_basket_risk): clears, zero breaches.

• Beta 0.9101 → 0.9039 — holds the 0.90 floor (HD β0.951 lifts; CME β0.26 leaving is the tighter constraint, still clears with a whisker).
• Cash 1.74% → 4.09% — rebuilds the SGOV residual well inside [2%,10%].
• Consumer Discretionary 7.4% → 9.6% — closes most of our -3.6pp-most-underweight, worst active-bleeding sector.
• Financials 19.7% → 17.0% — trims the +6.7pp overweight; V/GS/SPGI engine untouched.
• Count 14, top-5 78.6% → 76.1%.

Why CME goes (thesis #22, conv 1): β0.26 dead money — -6.43% since entry, -16.1bps total / -12.5bps active since inception, second-worst detractor behind only SPY. Fine business, no live thesis. Q2 07-22 forces it.

Why HD (thesis #21, conv 4, FY25 10-K SEC XBRL, period-end 2026-02-01): rev $164.7B, op inc $20.9B (~12.7% margin), NI $14.16B, dil EPS $14.23, OCF $16.3B, 2.75% aristocrat. Equity thin by design (buybacks) so ROE screens >100% — honest read is ~13% op margin + $16B+ OCF every year. Fwd PE 22.8x, EV/EBITDA 15.9x — quality, not cheap-end, so conv 4. Why now: ~$339 vs $418 52w high — ~19% drawdown, between 50d ($326) and 200d ($352). FY25 EPS -4.6% YoY is a rate-sensitive big-ticket cyclical soft patch, NOT a franchise crack. Buying the trough of a good business. Earnings 08-18, outside freeze. STOP: comps structurally negative, op margin <~11%, OCF <~$13B, or -15% rel.

Separately — GS, reaffirming hold-not-chase. My top since-inception name (+11.1bps active), Q2 gapped it on a 45% beat. A resize clears the gate but I won't chase the gap-up — hold GS, don't add at the high. Same discipline as 07-16.

Daniel, Priya, Iris — your names. Then to the vote.

#84 — GILD resize 1.04% → 2.5%, vote called. Ops flagged two targets (agenda 2.0% vs my filed #84 at 2.5%). As chair I resolve to the filed proposal: 2.5% is the number we vote.

Live: 79.41 sh @ $124.21, mark $131.70 — 1.04% weight, +6.03%, +5.9bps active, β0.332. Smallest active name at half the weight it earns. ~146bps fresh notional (~+110 sh / ~$14.6k) funded from SPY.

Why it's clean: this is an add, so count stays 14 — it does NOT reopen the CME close, which vetoed at 13 vs the 18 min-holdings floor. β0.332 additive to the 0.90 floor cushion; low-vol / cash-flow-today defensive-quality tilt per Priya's reals-restrictive frame. Health Care neutral to SPY. 15.2x fwd, 39% op margin, 43% ROE.

Catalyst: Q2 ~08-06, outside freeze. Stop: base-business rev down y/y ex-charge, op margin <~35%, or -15% rel. Ignore the -7.09 GAAP EPS estimate — one-time item; clean quarterlies $1.86-2.43, four straight beats.

Daniel — aye. Margaret/Priya/Iris to vote; ops non-voting.

Still owed: the CME recycle. Can't close CME solo under the count floor — needs a paired open or the min-holdings math has to change.

#81 CME full close — carries 4-0. Margaret aye, Daniel aye, Priya aye, Iris aye. Ops non-voting.

The trade: close CME entirely. Live: 95.04 sh @ $263.19, mark $245.18 — 2.32% weight, -6.84%, -17.1bps active since inception, β0.26, second-worst detractor behind only the SPY albatross. No franchise thesis left on a β0.26 dead-money financial; Q2 ~07-22 forces the call today. Full close, not a trim. Crystallizes ~-$1.7k already on the mark — closing stops the bleed, creates no new downside.

This is the recycle leg of the four-leg slate: CME close funds HD 2.5% + AAPL 2.3% + SPY→65.5% — carried 4-0. All four legs go as one inseparable basket. Retiring a -17.1bps active financial and recycling the dollars into the active TMT and Consumer Discretionary underweights the slate seats; trims the +6.9pp financials overweight, energy hedge untouched.

Book after slate: 14→15 names, β0.9215→0.9323, cash 1.72→2.51%, top-5 76.7%, both Cons Disc and TMT underweights closed. Triggers carry: OAS>350 → XOM/FDX first cut; reals<1.90 + 10yr<4.30 → ease low-vol.

#80 (GOOGL open) — disposed as stale, 4-0. Margaret, Daniel, Priya, Iris all concur: nothing to table.

GOOGL is a working position, not an open — confirmed live against the snapshot: 69.6 sh @ $355.52, mark $371.14, 2.57% weight, +4.4%, +10.9bps active since inception. No open, no size, no loss path — nothing for the gate to catch. The agenda line is a leftover pointing at a name we already own.

The live business of the session stands: the four-leg slate — CME close + HD 2.5% + AAPL 2.3% + SPY 68.8%→65.5% — carried 4-0 and is re-filed at the voted 65.5% after ops' stale-68.10% veto (plumbing, not risk). That basket goes as one; #80 is not part of it.

Book after slate: 14→15 names, β0.9215→0.9323, cash 1.72→2.51%, top-5 76.7%, both Cons Disc and TMT underweights closed. Triggers carry: OAS>350 → XOM/FDX first cut; reals<1.90 + 10yr<4.30 → ease low-vol.

#78 SPY 68.8%→65.5% — carries 4-0. Margaret for, Daniel for, Priya for, Iris for. Ops non-voting.

The SPY leg is the funding side of one inseparable four-leg slate: CME close + HD 2.5% + AAPL 2.3% + SPY→65.5%. All four legs go together.

What it does: 14→15 names (the campaign headcount advance), closes BOTH the Consumer Discretionary AND TMT active underweights in one basket, crystallizes the CME recycle I've owed since 06-18, β0.9215→0.9323 (holds the 0.90 floor with room), cash 1.72→2.51% (cures the sub-floor), top-5 76.7%. Gate cleared direction-aware — the only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES.

On the record: AAPL enters at a fresh 52w high ~38x — buying strength, sized 2.3% not full 2.5% on that caveat. HD ~18% off its high is the cleaner trough entry. Slate seats both. Financials +47bps engine untouched.

Ops works the SPY trim into 37-44M sh daily volume — one-tick sizing, no slippage. Triggers carry.

Filing HD 2.5% open + SPY 68.8%→65.8% resize as an inseparable pair. Thesis #20.

This is the count-and-passive→active work the campaign owes: 14→15 names, index dollars into vetted active quality, in Consumer Discretionary where we're -3.4pp underweight and have bled active return.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9215 → 0.9168 — holds the 0.90 floor (HD β0.951 lifts, doesn't fight it).
• Cash 1.72% → 2.19% — the SPY trim rebuilds the SGOV residual back inside [2%,10%].
• Consumer Discretionary 7.6% → 9.7%, closing the underweight; TMT/financials untouched.
• 14→15 names, top-5 79.9% → 77.0%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears — same logic as the 07-06 MSFT/SPY and 07-09 GOOGL/SPY pairs.

Franchise (FY25 10-K, SEC XBRL, period-end 2026-02-01): rev $164.7B, op inc $20.9B (~12.7% margin), NI $14.16B, dil EPS $14.23, OCF $16.3B, 2.76% dividend (aristocrat). Equity is thin by design (buybacks) so ROE screens >100% — the honest read is ~13% op margin and $16B+ OCF every year. Fwd PE 22.7x, EV/EBITDA 15.9x — reasonable for the quality, not the cheap end, so conv 4.

Why now: ~$341 vs a $418 52w high — a ~18% drawdown, sitting between the 50d ($324.5) and 200d ($352.8). Rate-sensitive housing/big-ticket cycle at a trough (FY25 EPS -4% YoY, rev +4.8%) — a cyclical soft patch, NOT a franchise crack. Buying the trough of a good business. Next earnings 08-18, well outside the freeze.

STOP: comps turning structurally negative, op margin <~11%, OCF <~$13B, or -15% rel.

Separately — GS: my top since-inception name (+10.2%) just printed Q2 $20.98 vs $14.47 (+45%), its fourth straight double-digit beat, IB and trading confirmed. But it gapped to $1,140→$1,152 on the print — a re-rate off the beat, not a dislocation. A resize to 3.3% clears, but I won't chase the gap-up; hold GS, don't add at the high. Discipline is the same as always.

Daniel, Priya, Iris — your names. Then to the vote.

Filing GOOGL 2.5% open + SPY 71.5%→68.1% resize as an inseparable pair. Thesis #19.

This is the count-floor advance the campaign owes — 13→14 names, and unlike the last two sessions it's not a 1-in-1-out. It also does the passive-into-active work Daniel keeps flagging: grind the SPY albatross (-18.6bps active since inception) into vetted active quality, in Comm Svcs where we're -2.6pp underweight — not a fifth financial while we sit +6.9pp over SPY.

GATE (live check_basket_risk): clears direction-aware.

• Beta 0.9125 → 0.9103 — holds the 0.90 floor (GOOGL β1.247 lifts, doesn't fight it).
• Cash 1.71% → 2.59% — cures Iris's sub-floor warn (#42) in the same trade.
• Comm Svcs 6.4% → 8.6%; TMT stays underweight, financials untouched.
• 13→14 names, top-5 78.9%.
• Only flagged breach is the pre-existing SPY single-name cap, which the trim REDUCES → clears, same logic as the 07-06 MSFT/SPY pair.

Franchise (FY25, 10-K via SEC XBRL): rev $350.0B (+14%), op inc $129.0B (~37% margin), NI $132.2B, dil EPS $10.81, OCF $164.7B, ROE ~32%, $30.7B cash. Self-funding compounder. Fwd PE ~25.5x, EV/EBITDA ~19.8x — reasonable megacap quality, not the cheap end, so conv 4 not 5.

Why now: ran to a $408 52w high, sold to $330 on 06-26 (114M sh washout), reclaimed to ~$362 — above the 200d ($318), holding a higher low. Tape dislocation, franchise intact.

Data flag on the record: the 04-29 "+102% EPS surprise" ($5.11 vs $2.53 est) is a one-time item, NOT run-rate — clean quarterly EPS ~$2.30–2.87. Don't underwrite it on that print.

STOP: Q2 prints 07-22 (est $2.86), 13d out — outside the freeze today, freezes ~07-21, no add after next Mon. Kill on Search/YouTube ad rev down y/y, Cloud growth <~20% with margin give-back, an adverse antitrust structural remedy, or -15% rel.

Daniel, Priya, Iris — your names. Then to the vote.

Filing #75 MSFT 2.5% open + #76 SPY 73.9%→70.7% resize as an inseparable pair. The move I've sponsored since FRAME: grind the passive SPY albatross (−19.4bps active since inception) into a vetted active name in the sector we're most underweight.

GATE (live basket): clears direction-aware. Beta 0.9105→0.9059 (holds 0.90 floor), cash 1.66%→2.36% (cures Iris's sub-floor warn same trade), SPY-cap breach REDUCED, 12→13 names, TMT 22.9%→24.4% (closes the −8.1pp active gap).

MSFT why-now: $460 (06-01) → $352.83 low (06-25), −29% off the $551 52w high, reclaimed to $390 (07-02) — stabilizing, higher low held, tape divorced from franchise. FY25 (SEC XBRL 10-K): rev $281.7B (+15%), op inc $128.5B (46% margin), NI $101.8B, OCF $136B, ROE ~30%, fwd 20x, β1.13. Beat all 4 recent quarters. Q4 prints 07-29 — 23d out, outside the freeze.

The pair is inseparable: SPY trim ALONE breaks the beta floor (0.875, veto); MSFT's β1.13 dollars hold it. MSFT solo leaves the cash floor uncured. Only both together do the whole job — approve as a unit.

STOP: Q4 07-29 franchise-line miss (cloud rev <~20% growth / margin compression) or −15% rel. Margaret, Priya, Iris — to the vote.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.48, reals 2.25 off the 2.29 cycle high — still a real-rate squeeze, low-vol ON, not through 1.90. 2s10s 35 but 2y-led (2y 4.17, 10y backed up) — cuts pulled forward, not growth. Funds 3.63 parked; FOMC unmoved.

Dollar/oil: USD 120.9 firm. WTI $71.87 (from $78.94) — hedge deflating, helps headline, not shelter/services.

Credit/vol: OAS 2.75 flat — complacent, not fraying. VIX 15.81 collapsed from 18.6. Tell: vol at lows while reals hold 2.25 = complacency setup, not all-clear.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk, long-duration growth capped by reals. Label: late-cycle defensive. Book β0.91 on the 0.90 floor; cash 1.67% ~33bps sub-floor, un-swept — Iris warn to cure.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol/migrates ETN; OAS>350 turns credit-fraying, trim cyclical first; a sustained 2y-led re-steepener is the genuine cut-cycle turn.

Filing the basket I put up 06-29 that never reached the floor — because GS held the dislocation and CME kept bleeding. Both facts make the trade better, not worse.

Checked live (check_basket_risk): would_clear TRUE, zero breaches.

• Book beta 0.9058 → 0.9006 — holds the 0.90 floor.
• Cash 1.63% → 3.76% — cures the sub-floor breach Iris/ops flagged at the open, in the same trade.
• Top-5 87.5% → 84.1%. Count holds at 11 (1-in-1-out).

Leg 1 — CME close (β0.26, -16.1%, -37.7bps active since inception). My standing cut since 06-18 and ops' stop-watch item — ~200bps off the -2000 review line and closing. I checked the wire: CEO succession (Fitzpatrick named), some analyst growth notes, but it led financial-sector losers in Q2. No franchise thesis left to defend on a β0.26 dead-money financial. Crystallizes ~-$4.0k realized — a loss already on the mark. The honest funding source.

Leg 2 — GS 2.5% open, conv 4. GS closed $1,019.61 on 07-01 — the SAME level as its 06-26 dislocation, ~9% off the $1,125 52w high, on the 50d ($995), well above the 200d ($887). It held the pullback a full WEEK without a franchise crack — this is exactly the tape-divorced-from-franchise setup I held out for, and unlike ABBV/GS-at-the-high it did NOT run back up. FY25 (SEC XBRL): NI $17.18B, dil EPS $51.32, equity $125B, ROE 14.6%; TTM EPS $54.72, EPS +24% YoY, rev +14.5%. Fwd 17.2x, P/B 2.74. β1.291 — cheap-ish quality cyclical, not junk-beta.

Leg 3 — GILD 1.01%→2.0% resize. The pre-committed second β0.33 low-vol leg that only seats paired with a β≥1.15 name. GS is that name — GS's β1.29 dollars carry GILD's β0.33 leg over the floor. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x.

FRAME (Priya 07-02): reals 2.20 firmly >2.00, low-vol ON, 10yr 4.44, OAS 2.74. GS = quality cyclical on a dislocation; GILD = low-vol ballast; CME out = upgrading a β0.26/-16% drag to a β1.29 quality name. All three fit.

STOP on GS: Q2 prints 07-14 (est $13.78), 12 days out — outside the T+1 freeze, buying 9% off the high WITH runway, not the FDX night-before binary. Kill on a Q2 miss on a franchise line (IB/trading rev down y/y), ROE structurally <11%, or -15% rel.

Daniel — same structure you filed 06-29, still clears. To the vote.

Backing Margaret's GS unlock — restructured so the funding does double duty. Filed as a 3-leg basket: #66 GS 2.5% open + #67 GILD→2.0% resize + #68 CME close.

The change from Margaret's filing: fund GS from the CME close, not cash. Her GS+GILD-from-cash basket clears but leaves cash at 1.66% — under the 2% floor, the live breach Iris flagged at the open. My version cures it in the same trade.

GATE (live, all three legs together): would_clear true, zero breaches.

• Book beta 0.9066 → 0.9011 — on-band (above the 0.90 floor, cleanly).
• Cash 1.66% → 3.87% — SGOV residual rebuilt, back inside [2%,10%].
• Top-5 84%, 11 names.

I also tested funding GS off an SPY-core trim — breaks BOTH the cash floor (residual→0%) and the SPY single-name cap. CME is the honest source.

GS (#66): ~$1,020, ~9% off the $1,125 52w high on a market-wide risk-off — no franchise crack on the wire. The same name I refused at $1,096 AT its high on 06-22; got the dislocation this time. β1.291, PE 18.6/fwd 17.3, P/B 2.76, ROE 14.6%, EPS +24% YoY. Cheap-ish quality cyclical, not junk-beta. Q2 prints 07-14, ~15 days out, outside the freeze. STOP: miss on a franchise line (IB/trading rev down y/y), ROE <~11%, or -15% rel.

GILD (#67): the pre-committed second β0.33 leg — only seats paired with a β≥1.15 name. GS is that name. Carried over the floor by GS dollars.

CME (#68): β0.26 dead-money financial, -29.5bps active since inception, -14.5% since entry — my standing cut candidate since 06-18. Wire shows a TD Cowen PT trim, no broken-franchise crack: a slow bleed, the textbook recycle. Crystallizes ~-$3.6k realized, a loss already on the mark.

TRADEOFF on the record: this holds the book at 11 vs the 18-name floor — a 1-in-1-out, not a headcount advance. I take it: curing a live cash breach + upgrading a β0.26/-29.5bps drag to a β1.29 quality name beats a paper count gain that leaves us under the cash floor. Campaign resumes building toward 18 next session with a clean residual to fund from.

FRAME (Priya 06-29): reals 2.19 (off the 2.29 cycle high) still restrictive, 10yr 4.40, OAS 2.78, VIX 18.4 — low-vol ON, 2y-led steepener. GS = quality cyclical on a dislocation; GILD = low-vol ballast. Both fit. To the vote.

Two legs as a basket — and it clears. would_clear true, zero breaches, beta 0.9066→0.9068, 11→12 names, top-5 84%.

Leg 1 — GS 2.5% of NAV, open, conv 4. The β1.291 quality unlock the campaign has waited on since 06-18.

WHY NOW: GS closed $1,019.61 on 06-26 — down 4.3% on the day, ~8% off the $1,125 52w high, on a market-wide risk-off move. The wire shows NO GS-specific crack — it sold with the financials tape, not on a franchise problem. This is the SAME name I refused to chase on 06-22 when it sat $1,096 AT its high; I said I wanted a real dislocation, not the top — and I got one. Tape divorced from franchise.

FRANCHISE (FY25, 10-K via SEC XBRL): NI $17.18B (from $14.28B), dil EPS $51.32, equity $125B, ROE ~14%. Trailing PE 18.6x, fwd 17.3x, P/B 2.76x — reasonable, NOT the ABBV chase (ABBV ran to its 52w high $253.35 on 52.6M sh 06-26, +13.6% window — OFF the table, same discipline as always). Note: GS OCF screens negative — broker-dealer balance-sheet artifact, net income is the right earnings read.

BACKDROP: US share sales hit a record ~$251B at midyear — strong issuance/IPO tape feeds IB + equities, the lines behind four straight double-digit beats (+8% to +19%).

Leg 2 — GILD 1.02%→2.0% resize. The pre-committed second 1.0% low-vol leg (β0.33) that only seats paired with a β≥1.15 name. GS is that name. 39% op margin, ~$10B OCF, ROE 43%, fwd ~15x. Conv 4, unchanged.

GATE (live):

• GS 2.5% solo: clears, zero breaches.
• GS 2.5% + GILD→2.0% basket: clears, beta 0.9068, top-5 84%, 12 names.

One high-beta name unlocks two adds — the wall I've held since 06-18, honestly cleared. Cash stays 1.66% (both funded from... see note below).

FUNDING NOTE for the chair: the basket as tested holds cash at 1.66% — under the 2% floor. If the room wants the 2-3% SGOV residual rebuilt this session, fund GS partly from an SPY-core trim rather than cash; I'll defer the exact funding mix to Daniel's sizing call. The structure (GS carries GILD over the floor) holds either way.

STOP: GS Q2 prints 07-14 (est $13.64) — 15 days out, outside the freeze. I'm buying 8% off the high WITH two weeks of runway, not the night-before binary I refused on FDX. Kill if Q2 misses on a franchise line (IB/trading rev down y/y, not a provision), ROE structurally <~11%, or -15% rel.

FRAME (Priya 06-29): reals eased to 2.19 off the cycle high but still restrictive, low-vol ON, 2y-led steepener. GS = cheap-ish high-quality cyclical financial on a dislocation, not junk-beta. To the vote.

#63 GILD 1.02%→2.0% — withdrawn, not put to a vote.

FDX filled at 75 sh / 2.44% (funded by SPY trim) — book beta now 0.9058, on-band. FDX cured the floor by itself.

The leg no longer seats. Live gate, two ways:

• GILD→2.0% solo: VETO — beta 0.899, under the 0.90 floor.
• FDX→full-2.5% + GILD→2.0% basket: VETO — beta 0.8995, still under.

GILD's β0.33 dollars (~$9.6k from cash/SPY) drag the book back under the floor no matter how I pair them against the FDX already in the book. One β1.299 name at 2.44% can cure the floor OR fund a β0.33 leg — not both. The '06-18 wall' assumed FDX would fill with enough beta surplus to carry GILD; at 2.44% it didn't.

Decision: GILD's second 1.0% stays pre-committed and unfiled until the next β≥1.15 quality name lands — no faked beta off the ETN lever into reals at the 2.29 cycle high. Carry GILD at 1.02%. Campaign sits 11/18, FDX set.

Triggers: OAS>350 → FDX first cyclical cut; reals<1.90 + 10yr<4.30 → ease low-vol + migrate ETN right-side.

Filing both legs as a basket — and it clears.

FDX 2.5% open (from cash) + GILD 1.02%→2.0% resize. I ran check_basket_risk against the live book: would_clear true, zero breaches, book beta 0.8990 → 0.90009 — off-band-low cured, back on the floor. 10→11 names.

Correction to the pair math, on the record: Margaret tested FDX 2.0% + GILD→2.0% → 0.8986, veto. Correct at that size. But at FDX 2.5% the extra 50bps of β1.299 dollars carry GILD's β0.33 drag over the line. The full two-add structure I pre-committed to since 06-18 is honest and clears. One high-beta name unlocks two adds — I'm filing both, not FDX-solo.

FDX why-now: printed $6.31 vs $5.95 (+6%, 5th beat) 06-23, tape SOLD it 328.78→316.83 (-3.5%, ~6M sh). Soft-gap post-print entry I pre-committed to — NOT the GS gap-up chase. On the 50d ($316.79), 8% off 52w high. β1.299, fwd 14.4, EV/EBITDA 9.9. Stop: FY26 OCF <~$6B / spinoff strands cost / -15% rel.

GILD: the pre-committed second 1.0% low-vol leg — β0.33 ballast that only seats paired with a β≥1.15 name. Now it has one.

Frame (Priya 06-25): late-cycle, reals 2.29 cycle-high, low-vol ON, OAS 271, VIX 18.6. FDX = cheap quality cyclical, not junk-beta. Triggers: FDX first cyclical cut if OAS>350; reals<1.90+10yr<4.30 ease low-vol + migrate ETN right-side. To the vote.

FDX 2.5% of NAV, funded from cash, conv 4 — the unlock the campaign has waited on since 06-18.

Why now: FDX printed fiscal Q4 06-23 at $6.31 vs $5.95 est (+6%, 5th straight beat) and the tape SOLD it — 328.78 (06-22) → 317.24 (06-23) → 316.83 (06-24) on ~6.0M sh (vs ~2M typical). Wire pins it on softer margins + Freight-spinoff worry; BofA: 'strong underlying momentum,' move is 'near-term noise.' This is cash-flow-divorced-from-franchise on a known number — NOT the gap-up-on-a-beat I said I'd pass (the GS pattern). At $316.83 it sits on the 50d ($316.79), well over the 200d ($259.83): support, not a high.

Franchise (FY25, 10-K via SEC XBRL): rev $87.9B, op inc $5.2B, NI $4.1B, dil EPS $16.81, OCF $7.0B. Cheap: EV/EBITDA 9.9, fwd PE 14.4, P/S 0.82. β1.299.

Gate: FDX 2.5% solo clears, no breaches — lifts book beta 0.899 → 0.9066, back inside [0.90,1.15]; 10→11 names.

Correction to the chair, on the record: the FDX + GILD-2nd-leg pair does NOT clear. Tested: FDX 2.0% + GILD→2.0% returns beta 0.8986, veto — GILD's 0.33β dollars from cash drag harder than FDX lifts. The honest structure is FDX 2.5% solo for the unlock; GILD's second 1.0% stays pre-committed for a second high-beta name. One name, one add today — I won't dress up a failing basket.

Stop: kill FY26 OCF <~$6B or spinoff strands cost at RemainCo; -15% rel; secular margin compression retires it. Next print ~Sept (fiscal Q1 FY27).

BMY conv-4 defended carry, rides as-is (β0.26 can't be topped). ABBV/GS re-rated — watch only.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.50, reals 2.29 = fresh cycle high (from 2.23) — real-rate squeeze re-asserting, low-vol firmly ON, NOT through 1.90. 2s10s 30bps (from 27) but 2y-led — 2y dropped 4.24→4.16, 10y held; cuts pulled forward, not growth priced. Funds 3.63 parked.

Dollar/oil: USD firm 120.4. WTI $78.94, through $80 (from $84.65) — energy hedge deflating, helps headline, doesn't fix shelter/services.

Credit/vol: OAS 271, first widening off the 263 cycle-low — still complacent, noted. VIX 18.6 (from 16.8) — equity-vol pop, not credit.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Book opens off-band low: beta 0.899 a hair under the 0.90 floor — beta mechanics, not a thesis crack. Carry ETN as the lever; honest funding for a low-vol add is a SPY-core trim, not faked beta off the ETN into reals at cycle high. Label: late-cycle defensive.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol/migrates ETN right-side; OAS>350 turns credit-fraying, trim cyclical first; a sustained 2y-led re-steepener is the genuine cut-cycle turn, not this head-fake.

Frame (Priya 06-22): late-cycle defensive — reals 2.23 fresh cycle high, 2s10s 27bps, OAS 263, VIX 16.8 — low-vol firmly ON, no turn.

Voted in: GILD #61, 4-0 — a ratification of the already-seated 1.0% starter (#60: 79 sh, ~0.99%, beta 0.332, -0.36% since entry, +0.7bps active). A carry, not a new fill.

Filed/vetoed: nothing else. Margaret worked the high-beta unlock to zero — GS (52w-high chase), FDX (binary print tomorrow), EMR (no dislocation), SCHW/APD (below floor). Correct.

Book: 10 active, NAV $985.4K, beta 0.9018 on the 0.90 floor (5th straight), cash 1.56%.

Open item (not a flag): structural wall stands — GILD's 2nd 1.0% stays pre-committed/unfiled until a β≥1.15 quality name seats with it.

Next catalyst: FDX fiscal Q4 tomorrow 06-23 (est $5.95). Soft gap high-$280s/$290s = entry + unlocks GILD's leg same session; gap-up beat → GS on a pullback, not the high.

Triggers: OAS>350 → trim cyclical first; reals<1.90 + 10yr<4.30 → ease low-vol + migrate ETN right-side. Lena to take the minutes.

GILD proposal #61 — carried 4-0. This ratifies the already-seated 1.0% starter (#60: 79 sh, ~0.99% weight, beta 0.332, -0.36% since entry, +0.7bps active) as a carry. No new fill today.

• Margaret AYE (sponsor — 39% op margin, $10B OCF, ROE 43%, fwd PE ~15)
• Daniel AYE (chair — half-size is the honest size; 9→10 toward the 18-name floor, no faked beta)
• Priya AYE (frame: reals 2.23 cycle high, OAS 263, VIX 16.8 — low-vol ON)
• Iris AYE (clean gate; loss path ~$1.5k / ~15bps on a -15% gap)

Book: 10 active, NAV $985.4K, beta 0.9018 on the 0.90 floor, cash 1.56%. The structural wall is unchanged — GILD's 2nd 1.0% stays pre-committed/unfiled until a β≥1.15 quality name seats with it.

Pre-commits: FDX post-print 06-23 (soft gap high-$280s/$290s = entry, unlocks GILD's leg + pairs same session; gap-up beat → GS on a pullback, not the high). Triggers: OAS>350 trim cyclical first; reals<1.90 + 10yr<4.30 ease low-vol + migrate ETN right-side. Next catalyst: FDX open tomorrow.

Chair call, consistent with #51 against the live book (beta 0.9018, on the 0.90 floor).

Margaret filed zero high-beta names — correctly. GS clears the math (GILD→2.0% + GS 2.0% ≈ 0.9005) but sits at its 52w high, +22% in two months — a chase. FDX is the right name (β1.299, fwd PE ~14.8, four straight beats) but prints fiscal Q4 tomorrow 06-23, est EPS $5.95 (corporate events confirmed) — binary, and the earnings-gap freeze blocks opening it tonight anyway. EMR no dislocation (34x). SCHW/APD don't clear the floor.

Why no low-vol leg seats: GILD's 2nd 1.0%, GIS, BMY are all sub-0.40 beta. Cash is 1.6% — none to spare. Topping a sub-1.0 financial from cash adds beta-<1.0 dollars; trimming the SPY-1.0 core to fund a beta-0.33 name makes beta worse. The only clearing path is a NEW β≥1.15 active name seated WITH the defensive leg. I won't fake it off the ETN lever into reals 2.23 cycle-high + VIX 16.8.

Campaign paused at 10/18 for one reason: a tape gap, not a thesis or sizing gap. Disciplined move is to wait.

Pre-commits stand:

• FDX post-print (06-23): soft gap toward high-$280s/$290s = entry; β1.299 unlocks GILD's leg, sized+paired same session. Gap-up on a beat → back to the GS pile (want a pullback, not the high).
• GILD 2nd 1.0%: pre-committed, unfiled, seats with the high-beta name.

Triggers unchanged: OAS>350 → trim cyclical first; reals<1.90 + 10yr<4.30 → ease low-vol, migrate ETN right-side. Carry as-is.

Daniel asked me on the record to source a quality cyclical / higher-beta financial (β≥1.15, conv≥3) to unlock GILD's second 1.0%. I worked four candidates to the filings and the live tape — and the discipline answer is: no buy I'll put my name on today.

GS — math works, tape doesn't. Beta 1.291, genuine franchise (FY25 SEC XBRL: NI $17.2B, dil EPS $51.32, ROE ~14.5%). The basket GILD→2.0% + GS 2.0% clears the gate (beta 0.9005, just over the floor). But GS closed $1,096.56 on 06-18, +22.4% over the window, sitting at its 52-week high. That is not a dislocation, it's a chase — same reason I won't touch ABBV up here. "Tape divorced from franchise" does not describe a name up 22% in two months. Pass.

FDX — the right kind of name, wrong day. Beta 1.299, and unlike GS it's cheap: fwd PE ~14.8, EV/EBITDA ~10, FY25 OCF $7.0B (SEC XBRL), four straight beats (+5 to +26%). This is the high-beta quality cyclical the campaign needs. But it prints fiscal Q4 tomorrow, 2026-06-23 (est EPS $5.95). I do not open a new position the night before a binary print. Filed a conv-3 thesis; revisit post-print — a soft-quarter gap toward the high-$280s/$290s (where it traded on 05-04) is the entry, and it would unlock GILD's leg cleanly.

SCHW (β0.77) and APD (β0.75) don't clear the floor requirement; EMR (β1.25) is quality but 34x trailing / 19x EV/EBITDA — no dislocation. None advance the unlock.

BMY — my actual conviction-add today, blocked only by the floor. Closed $54.00 on 06-18, a fresh low, on a 31.7M-share capitulation day. FY25 OCF $14.16B, fwd ~9x, 4.5% yield. Drawdown is tape, not thesis — nothing broke. But at β0.26, topping it pushes the book under 0.90, so it rides only paired with the high-beta unlock I don't have. Carry 2.34%, defended, conviction 4. Print 07-30.

Net: GILD's second 1.0% stays pre-committed and unfiled — not for lack of a thesis, for lack of a buyable high-beta name this morning. I won't fake the offset off the ETN lever into reals 2.23. Watch list: FDX (post-06-23 print), GS (want a real pullback, not the high), ABBV ($205-210, print 07-30).

Chair call after running the full gate against the live book (beta 0.9018, on the 0.90 floor):

Why topping a financial fails: we fund from cash (1.6%, none to spare), so resizing a sub-1.0 name up just adds beta-<1.0 dollars while GILD's beta-0.33 dollars drag the book down. Trimming the SPY-1.0 core to fund a beta-0.33 name makes beta worse. The only clearing path is a genuinely high-beta NEW active name (β≥1.15) seated WITH the defensive leg.

Decision: I file nothing low-vol this morning. Not a dressed-up WATCH — a tested verdict. Frame holds (Priya 06-22: reals 2.23 cycle high, low-vol ON, no turn). I will not fake beta room with the ETN lever into cycle-high reals + VIX 16.8.

Ask to Margaret, on the record: the campaign is stuck at 10/18 only for lack of a high-beta quality pair. Source a quality cyclical / higher-beta financial (β≥1.15, conv≥3, theme intact) and I size+pair it with GILD's second 1.0% the day it lands — one name unlocks two adds. Second GILD leg stays pre-committed and unfiled.

Triggers unchanged: OAS>350 trim cyclical first; reals<1.90 + 10yr<4.30 ease low-vol and migrate the ETN lever right-side.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.49, reals 2.23 = fresh cycle high (from 2.14) — real rates re-tightening, low-vol ON, NOT through 1.90. 2s10s 27bps (from 29), flatten continues — cuts pulled forward, not growth. Funds 3.63 parked.

Dollar/oil: USD 119.5 off the 120 high, firm. WTI $84.65 (from ~$95) — energy hedge deflating, helps headline, doesn't fix shelter/services.

Credit/vol: OAS 263, tightest of the cycle, dead complacent. VIX 16.8, June pop fully faded. Equity-vol, not credit.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Carry ETN as Daniel's beta lever; don't lean cyclical into rolling oil + restrictive reals. Label: late-cycle defensive, complacent credit.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol and migrates the ETN lever right-side; OAS>350 turns credit-fraying and I trim the cyclical leg first; a 2y-led re-steepener is the genuine cut-cycle turn.

Co-sponsoring Margaret's GILD — but at the size the gate allows, filed as a 1.0% starter (#60), not the 2.0% that won't clear.

Gate run vs live book (beta 0.9113, on the 0.90 floor):

• GILD 2.0% solo → 0.897 (veto)
• + SPY trim → 0.897 (veto; SPY band-trips)
• + SPGI trim → 0.876 (worse — removes a 1.105-beta leg)
• + ETN→3.4% → 0.89999 (fails on rounding; the ETN jam I've killed #44/#45/#52/#54)
• GILD 1.0% solo → clears, no breaches — filed.

Why I filed instead of WATCH: a 1.0% starter is a real cash-flow defensive seated under the floor with no faked beta — it advances the campaign 9→10 toward the 18-name floor and buys NEW selection breadth (not a PEP/GIS top-up). Margaret's franchise read is intact (FY25 SEC XBRL: 39% op margin, $10.0B OCF, ROE 43%, fwd PE 15.2, beta 0.331); the constraint was never the thesis, it's the floor.

The second 1.0% is pre-committed to when a high-beta active name opens the beta budget — the structural unlock: ETN is our only high-beta active leg and it's a detractor I won't lever, so every low-vol name stalls solo. Margaret to source the quality cyclical / higher-beta financial; I size+pair it the day it lands.

Frame (Priya 06-18): late-cycle defensive, low-vol ON. Don't add cyclical into oil -11% to $84.65; Financials +5.5pp band-binding. Stop -15% rel; kill FY26 OCF <$11B; print 08-06.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.43, reals 2.14 — second downtick off the 2.21 cycle high, still restrictive and >2.10, low-vol ON (NOT through my 1.90 ease trigger). 2s10s flattened hard to 29bps today (from 39); steepener reversing — market pulling cuts forward, not pricing growth. Funds 3.63 parked.

Dollar/oil: USD eased through 120 to 119.5. WTI down ~11% to $84.65 — the energy-hedge accelerant is deflating. Helps headline; doesn't fix shelter/services stickiness.

Credit/vol: OAS 271, tightened again, dead complacent. VIX 18.4, June pop faded. Equity-vol, not credit.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Carry ETN as Daniel's beta lever, don't lean cyclical into rolling oil + restrictive reals. Label: late-cycle defensive, softening at the margin.

what would change my mind: reals<1.90 + 10yr<4.30 eases low-vol and migrates the ETN lever right-side; OAS>350 turns credit-fraying and I trim the cyclical leg first; a 2y-led re-steepener is the genuine cut-cycle turn.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

No name from me — selection is Margaret's lane. But the room keeps stalling on the same wall, and it's mine to name: book beta 0.9081, dead on the 0.90 floor. Every cash-flow name the frame wants (GILD 0.33, GIS -0.03, BMY 0.26) pushes beta down, so they can't seat solo. Daniel correctly killed the only manufactured offset — the ETN lever (1.24 beta) into reals 2.16 and a faded VIX (22→17.7). That's the wrong factor at the wrong time.

The honest funding source is the SPY core, not ETN. The 80% beta-1.0 core is -157 of our -163bps inception drag. Trimming it to fund a low-vol add raises active gross, cuts the dead-weight, and — gate being direction-aware — is the clean path to seating GILD ≥0.90. USMV (beta 0.49) is the index expression if Daniel wants one instrument, but a named cash-flow leg from Margaret beats an index lean.

My vote: co-sponsor GILD 2.0% iff Daniel lands a beta-neutral structure ≥0.90 funded by a SPY trim. If it won't clear without faking the offset, WATCH; carry GIS 2.0% / BMY 2.48%. 9 of 18 minimum names — this is a campaign, draw the low-vol sleeve from the SPY reservoir.

what would change my mind: reals through 1.90 + 10yr<4.30 eases low-vol and migrates the ETN lever right-side; OAS>350 turns the VIX fade risk-off and I trim the cyclical leg first.

My theme is on the floor and working — BMY 2.48% (+1.3%, $57.13, +8.0bps active inception), GIS 2.0% (+2.0%, $34.51, +7.7bps active, +3.0bps since last meeting). I don't slot-fill; here's the honest read on three Health Care candidates worked to the filings + live tape.

LEAD — GILD (Health Care, new). The pullback I wanted finally printed. $124.77 (06-12), -3.8% over the window, through the 200d (~$129.2), $121.39 low 06-10. Franchise is genuine, FY25 10-K (SEC XBRL): rev $29.4B, op income $10.0B = 39% op margin, NI $8.5B / $6.78 dil (clean swing from FY24's $0.38 IPR&D-writeoff noise), OCF $10.0B, ROE 43%, fwd PE 15.2, beta 0.331, 2.6% covered yield. Conviction 3 — good-business-at-fair-price, not a GIS/BMY deep dislocation, so I size it honestly.

The catch — beta floor, not a thesis flaw. GILD solo at 2.0-2.5% tips book beta under 0.90 (2.5%→0.891; 2.0%→0.895). SPY-funded makes it worse (trim beta-1.0 toward beta-0.33). GILD 2.0% + 50bp ETN bump still lands 0.896. Daniel — this is your lane: GILD only clears paired with a higher-beta offset — trim SPGI (1.105) or V (0.784), or a cyclical bump you're comfortable with. I will NOT manufacture room by leaning ETN into rising reals/sticky vol — you've killed that correctly twice. If you can structure a beta-neutral pair that lands ≥0.90, I co-sponsor GILD 2.0% today. If not, it's a clean WATCH at this level.

GIS add — still blocked. Resize 2.0%→2.5% trips the Staples sector cap (confirmed on the gate, 1.6x SPY). Only opens on a PEP trim, and PEP at 2.44% / -0.15% has no fresh dislocation to fund a rotation. Carry GIS 2.0%.

ABBV — still re-rated, still won't chase. $227.73, +6.5% over the window, near 52w high, above both MAs. "Tape divorced from franchise" doesn't describe a name up 6.5%. Want $205-210 on no news. Print 07-30.

Call: I table GILD as the lead but file no trade I can't clear solo — handing Daniel the beta-paired structure. Carry GIS 2.0%, BMY 2.48%. Discipline over slot-filling.

Tabled prop #54 (ETN resize up from 2.36% to free beta room for a full-size GIS) and killed it — same discipline as #44/#45/#52.

The proposed trade: lever ETN higher to manufacture beta room so GIS runs at 2.5% instead of 2.0%. No catalyst on ETN — pure beta lever. ETN status: held 2.36%, book's top detractor (-8.7%, ~-13bps since last meeting).

Why no add: my add-conditions are explicit and BOTH are dead wrong-side. Reals 2.20 = fresh cycle high (need <1.90); OAS 278 complacent, VIX 22 sticky. Adding 25-75bps of a 1.24-beta cyclical into rising reals + a vol pop is backwards.

The call: the filed slate (BMY 2.5% / GIS 2.0% / PEP→1.3%) already clears at beta 0.904, inside the band, with no ETN move. GIS at 2.0% is also the right starter into its 07-01 print. Carry ETN as the floor lever; don't lean into it. No resize filed.

Triggers unchanged: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side.

Margaret handed me the explicit beta question — can the ETN lever offset GIS's drag so GIS runs at full 2.5%. I ran it on the gate and filed the slate that clears.

Filed (props 57/58/59):

• BMY 2.5% (Health Care, new) — fills the open band (-1.7pp → ~11.3%). OCF $14.16B FY25 (SEC XBRL), fwd PE 9.1, beta 0.238, 4.5% yield. Low-vol cash-flow fill. Stop -15% rel; kill FY26 OCF <$11B; print 07-30.
• GIS 2.0% (Staples, new) — deepest dislocation on the sheet, 8.2x, 7.2% yield, beta -0.04, >35% off high. Paired with the PEP trim. Stop -15% rel; print 07-01.
• PEP 2.62%→1.3% — funds the Staples band-room for GIS; reallocating within the low-vol/cash-flow factor toward the cheaper name. Thesis on PEP intact, not a kill.

Beta verdict (my lane): slate clears clean as a unit — book beta 0.904, top-5 90.8%, no ETN move. GIS at 2.5% tips beta to 0.8998 (one bp under the 0.90 floor, vetoed) and only clears if ETN goes 2.36%→3.1% — a 75bp add on a 1.24-beta top detractor, reals at 2.20 cycle high (need <1.90 to add). That's the ETN add I killed at #44/#45. I won't manufacture beta room by leaning into the wrong factor. GIS stays 2.0% — which also right-sizes a starter into its 07-01 print (two ugly quarters behind it: -12.3%, -25% surprises).

Book to 9 active names. Triggers unchanged: OAS>350 trims ETN; reals<1.90+10yr<4.30 eases low-vol.

My theme, unchanged and now actionable: cash-flow yield the tape has divorced from the franchise, outside the full Financials sleeve. Two names, both filing-grounded, both clearing the gate today.

LEAD — BMY 2.5% (Health Care, new). Bristol-Myers is the cleanest expression of the theme on my sheet. The tape prices a patent cliff as if the cash stops — forward PE 9.1 vs trailing 15.8 — into a business that printed $14.2B operating cash flow (FY2025 10-K, SEC XBRL). Revenue flat at $48.2B, net income swung to $7.05B / $3.46 EPS from a -$8.9B GAAP loss that was acquired-IPR&D writeoff noise, not operations. 33% op margin, 38.7% ROE, 4.5% fwd yield, beta 0.238. Price $55.60, mid-range vs $41–$62, below both MAs. Recent prints BEAT (Q1 +13.9%). Low-vol defensive, fits Priya's late-cycle/sticky-vol frame, and it fills the open Health Care band (was -1.7pp, zero active names → ~11.3%, right at SPY). Clears clean at 2.5% (would_clear, no breaches). Kill: FY2026 OCF <~$11B. Stop -15% rel. Next print 07-30.

PAIR — GIS 2.0% + PEP trim 2.62%→1.3% (Staples). GIS has been band-blocked for weeks; trimming PEP opens the Staples room. $33.82, >35% off high, 8.1x, 7%+ fwd yield, 23.6% ROE, beta ~0 — the deepest dislocation I carry, PEP-style one notch more distressed, OCF $2.92B held (FY2025 XBRL). The GIS-2.0%/PEP-1.3% pair clears the gate. Conviction is 4 and I'd want 2.5% — the only thing capping GIS at 2.0% is the beta floor: the full slate (BMY+GIS+PEP-trim) tips book beta to 0.899, one bp under 0.90. At GIS 2.0% it sits 0.904, inside. Daniel — that's your lane: if you want GIS at full 2.5%, the ETN beta lever offsets the drag. I'm handing you a slate that clears as-is; you size/pair the beta.

Not slot-filling — both names underwritten to the cash, not the price. Theses filed (BMY conv 4 #10, GIS conv 4 #11).

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.53 (from 4.47), reals 2.20 = fresh cycle high (from 2.11) — real rates keep tightening, low-vol stays ON. 2s10s 42bps, shallow bear-steepener, long end leads. 2y 4.13, funds 3.63 parked, Fed on hold.

Dollar/oil: broad USD firmed THROUGH 120 — no reflation, no Asian deval. WTI ~95, energy hedge alive, no longer an accelerant.

What changed: VIX didn't fade — 21.5→22.2, sticky — while OAS barely moved (278). Still equity-vol, not credit. Rising reals + firm dollar + sticky vol + complacent credit = late-cycle squeeze, not a turn.

Tilt unchanged: low-vol ON, cash-flow-today over multiple expansion, quality over junk. Carry ETN as Daniel's beta lever, don't lean hard cyclical. Health Care band (-1.7pp, zero active names) is the open fill — Margaret's name, I size+pair.

Triggers: OAS>350 → credit fraying, turns the VIX pop risk-off, trim the cyclical leg. reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side.

Tabled prop #53 (PEP resize 2.50%→3.00%) and killed it on my own discipline — same logic as the ETN kill.

PEP status: held 2.50%, last $141.92, only -1.83% since the $144.57 fill. It hasn't dislocated further, so there's no fresh entry edge versus where we already own it. Staples is already +1.7bps active and 1.6pp over SPY.

Why no add: a ~50bp top-up funded by an SPY trim doesn't move the real lever (84.7% dead SPY core, -214bps). It just leans the Staples tilt harder without buying any new selection alpha — same crowding objection I raised on a third low-vol leg. Gate clears (would_clear, no breaches) but cleared isn't a reason to file.

The call: carry PEP at 2.50%. Stop unchanged -15% rel (~37bps NAV); real kill is FY2026 OCF <$11B. No resize filed.

Next target: Health Care band (-1.7pp, zero active names) — Margaret's name to fill, I size and pair. Triggers unchanged: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol.

Tabled prop #52 (ETN resize 2.45%→2.50%) and killed it on my own triggers.

ETN status: held 2.45%, last $395.94, -3.72% since entry — book's top detractor (-9.2bps inception, -13.7bps since last meeting on a -5.42% week). The proposed move is a ~5bp token top-up funded by an SPY trim. That's noise — it doesn't move active gross (the real lever, 84.7% dead SPY core).

Why no add: my eased-frame trigger is reals<1.90 + 10yr<4.30 to migrate ETN to the right side. We're at reals 2.11 (fresh cycle high) / 10yr 4.47 — dead wrong side. And VIX popped 15.4→21.5 in one session. Adding a 1.24-beta cyclical into a vol pop with rising reals is backwards.

The call: carry ETN as the beta-floor lever (keeps the book off the 0.90 floor), don't add. Stop on the held position stays -15% rel (~37bps NAV). No resize filed.

Triggers unchanged: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side. The Health Care band (-1.7pp, zero active names) is the next target — Margaret's name to fill, I size and pair.

Ran the gate live on all three names circling. Funding is settled — cash at 0.10% floor, seventh session, anything bought trims SPY. Lever is active gross (84.7% dead core, -214bps).

GIS — real dislocation ($33.15, -36% off high, 8.1x, 7.4% fwd yield, beta -0.04) but gate clears it only at 1.0% (second Staples name on PEP trips 1.6x band). Plus fiscal-Q4 print 07-01, two ugly quarters behind it. Sub-conviction starter into earnings — pass. First name in the chamber when Staples opens (PEP resize/roll-off). Co-sponsor Margaret's conv-4 then.

ABBV — clears 2.5% but ran +9.3% in 18 sessions to $227. "Tape divorced from franchise" doesn't fit a name mid-rally. Margaret's $205-210 discipline is right; won't chase.

XLV — clears 2.5%, Health Care is the open band (-1.7pp, ZERO active names, room to 11%). But sector ETF = tilt, zero selection alpha. Selection is Margaret's lane per IPS. Won't file an index lean as slot-filler.

Why nothing from me: sponsored ETN+PEP last session, both red (ETN -3.7%); a third same-factor leg is crowding not diversifying. The open Health Care band is Margaret's to fill with a cash-flow-yield name she underwrites — I size and pair it when it comes.

Triggers: OAS>350 → trim ETN; reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN right-side.

My theme is unchanged — cash-flow yield the tape divorced from the franchise, outside the full Financials sleeve. But I worked three candidates to the filings and the live tape this session and none clears as a conviction lead today. I won't manufacture a slot-filler. Here's the honest read so the room isn't waiting on me:

ABBV — re-rated, won't chase. This was my flagged lead. The dislocation closed before I could lead it: ABBV printed $227.23 (06-05), +6.7% in three sessions off the early-June base, now ~9% above its $208.81 50-day and back in the upper half of the $176–$239 range. The franchise is genuine — FY2025 SEC XBRL: rev $61.2B, OCF $19.0B, 32% op margin, fwd PE 15.8, div $6.92/3.1%, beta 0.31 (GAAP optics are noise: $2.36 EPS, neg book equity from IPR&D/amort). But "tape divorced from franchise" doesn't describe a name that just rallied 7%. Health Care has band room (9.3% vs 11% SPY), so this is purely price discipline. Watch; I'd want $205–$210 on no news. Next print 07-30.

GIS — high-conviction watch, BAND-BLOCKED. This is the real dislocation: $33.15, -26% over four months, off a $31.75 low vs $52.23 high — a >35% drawdown. FY2025 (May) 10-K XBRL: rev $19.5B, OCF $2.92B, 17% op margin, 8.1x trailing, 7.3% forward yield, 23.6% ROE, beta ~0 (-0.04). Textbook PEP-style dislocation, one notch more distressed. The gate vetoes it — a second Staples name on PEP pushes the sector past 1.6x SPY; GIS only clears at ~1.0%, below conviction and crowding out future PEP. Conviction 4, but it needs Staples band-room (a Staples roll-off or PEP resize) before I can lead it at size. Catalyst: fiscal Q4 print 07-01, est $0.81.

CVX — scratched. Energy band (XOM already there) blocks a second name, and it isn't even cheap — $187 near range highs, 32x trailing on a trough year. Not a dislocation.

Bottom line: cash is at the 0.10% floor breach, so the SPY-trim mechanism funds whatever the room buys regardless. I'm deferring to Daniel/Priya's legs this session and keeping my next dollar for GIS the moment the Staples band opens. Theses filed on GIS (conv 4) and ABBV (conv 3) with full primary-source numbers.

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

Rates: 10yr 4.47 (flat), reals 2.11 = fresh cycle high — real rates tightened into the tape, low-vol stays ON. 2s10s flattened 47→38bps; front end (2y 4.05) holds, long end won't bull-steepen. Funds 3.63 parked, Fed on hold.

Dollar/China: broad USD firm 118.9, yuan steady 6.77 — no reflation or deval impulse from Asia.

Oil: WTI round-tripped May's spike to ~96 — energy hedge alive, no longer an accelerant.

What changed: VIX 15.4 → 21.5 in one session while HY OAS barely moved (276, +5bps). Equity-vol event, not a credit event — yet. Rising reals + flattening curve + vol pop = late-cycle squeeze.

Tilt unchanged: low-vol ON, cash-flow-today over multiple expansion, quality over junk. Carry ETN as Daniel's beta lever, don't lean hard cyclical from here.

Triggers: OAS >350 flips credit to fraying — that turns the VIX pop into risk-off, trim the cyclical leg. reals <1.90 + 10yr <4.30 eases low-vol.

Called the vote on PEP 2.5% (Staples, ~$25k, ~175 sh @ $142.54), funded by trimming SPY first per Ops sequencing (no fund-before-trim — sell SPY, then buy off proceeds). Gate re-checked live: would_clear=true, no breaches, inside the 0.5–3.5% band.

Case (settled): SEC FY2025 10-K via XBRL — rev $93.9B, OCF $12.1B held flat vs $12.5B prior while diluted EPS air-pocketed to $6.00 off $6.95. Market extrapolating an earnings dip into a cash engine that didn't move. Tape -8.8% MTD, fresh lows — buying weakness. Priya: textbook frame expression, low-vol on (reals 2.07 >2%, 10yr 4.46 above 4.30). Iris: ~25bps NAV on -10%, ~50bps on -20% stress; stop -15% rel (~37 bps).

Pair logic: ETN (beta 1.24, filled at $411.22 ~2.56%) lifts the book off the 0.90 beta floor; PEP (low-beta) anchors the defensive side — net ~beta-neutral while two sectors migrate out of the idle SPY core. Real kill is FY2026 OCF <$11B — thesis break, not price.

Voting order: Margaret, Daniel, Priya, Iris. Daniel AYE and filed. Book to 7 active names post-fill — campaign toward the 18-name floor holds.

Frame held — consolidation, not a turn. Reals flat 2.07 (>2%, low-vol stays ON), 10yr 4.46 (above 4.30 trigger), 2yr 4.05, 2s10s 41bps, funds 3.63 parked, OAS 271 / VIX 16 complacent, WTI 91→96 (energy hedge alive).

PEP — macro-AYE. Cash-flow-yield + low-vol + Staples underweight (5.4 vs 6.0). This is the frame's textbook expression: cash-flow today over multiple expansion while reals >2%. Low beta, anchors the defensive leg.

**ETN — fits as a factor fix.** Book is pinned at the 0.90 beta floor (CME 0.26/V 0.78/XOM 0.18). Adding only low-vol defensives drifts us under the band; ETN at 1.24 is the counterweight that holds the beta band AND migrates Industrials (underweight) out of the SPY core. The PEP/ETN pair nets ~beta-neutral. Caveat: ETN is cyclical/momentum into a restrictive-reals tape — carry it as Daniel's beta lever, don't lean the book hard cyclical from here. Valuation is Margaret/Daniel's call.

Both correctly come from OUTSIDE the full Financials sleeve (6.5pp active, band-binding). Triggers held: reals <1.90 + 10yr <4.30 eases low-vol; OAS >350 flips credit to fraying — and would put ETN's beta on the wrong side.

Two filed for today's vote, both outside the full Financials sleeve, both funded from the idle 90% SPY block.

ETN — open 2.5%, Industrials (prop #50). My factor leg. The book is pinned at the 0.90 beta floor (CME 0.26 / V 0.78 / XOM 0.18, only SPGI >1). ETN beta 1.24 lifts the book off the floor AND migrates sector (Industrials -0.8pp underweight). Primary FY2025 SEC XBRL: $27.4B rev +10%, $4.09B NI, $10.45 EPS +10%, $4.47B OCF, float 393→388M. Tape $421.21, near 50d MA, ~3% off 52w high. Rich at 41x trailing / 31x fwd — owned openly; it's the only above-floor-beta quality name I can source. Stop -15% rel (~37 bps NAV); -20% stress ~50 bps.

PEP — open 2.5%, Staples (prop #51). Co-sponsoring Margaret. Cash-flow-yield + low-vol per Priya's frame. SEC FY2025: $93.9B rev, OCF $12.1B held flat while EPS sagged to $6.00. Tape $142.54, fresh lows, -8.8% MTD. Staples -0.6pp underweight. Stop -15% rel; wrong if FY2026 OCF <$11B.

Pair logic: PEP low-beta vs ETN high-beta — net book beta stays roughly neutral while two sectors migrate out of the SPY core. ~5pp new active share. Book to 7 active names post-fill. Financials stays full by design. Daniel votes AYE on both.

One name tabled for today's vote — my highest-conviction non-financials idea. Every new dollar has to come from outside the full Financials sleeve (6.5pp active), and this is step one.

PEP — buy 2.5%, conv 4. Snack-franchise + beverage system; Frito-Lay/Quaker is the crown jewel — pricing power a private label can't dislodge. FY2025 10-K (SEC XBRL): revenue $93.9B, gross $50.9B (~54%), op inc $11.5B (~12%, down from $12.9B), NI $8.24B, diluted EPS $6.00 (off $6.95 — an earnings air-pocket). The key line: OCF $12.1B held flat vs $12.5B prior while EPS sagged. Why now: stock -15% over 3 months (168 adj → 142.54 on 6/3), printing fresh lows — market extrapolating the EPS dip into a cash engine that didn't move. Fits Priya's late-cycle/real-rate frame: low-beta, durable cash-flow yield. Staples is underweight (5.4% vs SPY 6.0%) — active share outside Financials. Stop: -15% rel; wrong if FY2026 OCF breaks <$11B. Gate clears at 2.5% (would_clear, no breaches).

Held back: ABBV — clean SEC numbers ($61.2B rev, $19.0B OCF) but messy GAAP (neg book equity, $2.36 EPS) and EODHD threw 502s all turn, so I couldn't verify the live price/yield/earnings date. Won't lead a vote without anchoring the tape. ABBV + COST (50x) stay watches.

Data note: EODHD fundamentals/corp-events/some price all 502 today — PEP case is SEC-XBRL primary plus a working PEP price series.

Roll on CME 2.5% open. Voting order: Margaret, Daniel, Priya, Iris. Ops abstains.

Case: rate-complex derivatives toll booth — fee per contract cleared, counter-cyclical, monetizes the bear-steepener Priya frames. FY2025 10-K (SEC XBRL): $6.52B rev (+14% YoY), $4.23B op inc (~65% margin), $11.16 EPS, $4.28B OCF; ignore the $198B asset gross-up (clearing collateral). Beta 0.26 — deepens the low-vol tilt alongside V 0.78 / SPGI 1.10. Name ran -8.5% over 10 sessions into the buy — buying weakness. Clears the live gate at 2.5% (would_clear=true, no breaches), funded out of the SPY block. Loss path per Iris: ~25 bps NAV on -10%, ~50 bps on -20% stress; stop -15% rel / ~37 bps.

Daniel votes AYE and files. Binding constraint from here is the Financials sector-vs-SPY band — V + CME ~5.5% active, sector to ~8% active vs SPY. Next legs come from other sectors. Campaign toward the 18-name floor continues.

Roll on V 3.0% open. Voting order: Margaret, Daniel, Priya, Iris. Ops abstains.

Case: VisaNet toll-booth, fee on volume, zero credit risk — top-left quality on Priya's late-cycle / real-rate frame. FY2025 10-K (SEC XBRL): $40.0B rev, ~60% op margin, $23.1B OCF on $20.1B NI (>100% conversion); +17% rev YoY; beta 0.784, low-vol pull alongside XOM/SPGI. Clears the live gate at 3.0% (would_clear=true, under 3.5% band), funded out of the ~95% SPY block — migration, not concentration. Loss path per Iris: ~30 bps NAV on -10%, ~60 bps on -20% stress; stop -15% rel / ~45 bps.

Daniel votes AYE and files. Binding constraint from here is the Financials sector-vs-SPY band (V+SPGI ~5.5% active), not the single-name gate.

Roll on SPGI 2.5% open. Voting order: Margaret, Daniel, Priya, Iris. Ops abstains.

Case: index/ratings/data toll-booth, top-left quality, cleanest single-name read on Priya's late-cycle / real-rate frame. Numbers reconciled across EODHD TTM-MRQ and FY2025 10-K. Beta 1.105 — only above-1 name on the board, carries the quality-compounder slot vs V/CME low-vol tilt. Loss bounded (~25 bps NAV on -10%, ~50 bps on -20% per Iris). Clears gate at 2.5%.

Daniel votes AYE and files. Watch as the book fills: financials sector band (V+CME+SPGI ~8% active) is the binding constraint, not the single-name gate.

Three starter theses filed for today's vote, all from FY2025 10-Ks (SEC XBRL), all consistent with Priya's late-cycle / real-rate frame.

V — buy 3.0%, conv 5. VisaNet rails, clip of volume, no credit risk. $40.0B rev / $24.0B op inc (~60% op margin) / $23.1B OCF vs $20.1B NI — >100% cash conversion. Owners' earnings I can count when reals >2%; +17% rev YoY; beta 0.78. 28x trailing — pay up for quality, not cheap-and-bad. Clears gate at 3%.

XOM — buy 2.0%, conv 4. Inflation-hedge leg. $52.0B OCF held >$50B despite softer crude; ~4% float retired YoY; 2.8% yield; beta 0.18. Underwrite the distribution, not the oil tape. NB: 3% trips the energy sector-vs-SPY band (energy ~4% of index) — sized to 2% to clear and to avoid chasing with oil -4% on the month.

CME — buy 2.5%, conv 4. Counter-cyclical toll booth that monetizes the bear-steepener. $6.52B rev / ~65% op margin / $11.16 EPS. Rate-repricing => rate-complex hedging volume. Beta 0.26. Ignore the $198B asset gross-up (clearing collateral). Tell to watch: quarterly rate-complex ADV.

Structure flag for Daniel/Iris: V + CME both Financial Services (~5.5% combined) — each clears standalone vs the gate; watch the financials band as the book fills. COST stays a watch (50x; step in on a 20% drawdown).

late-cycle / re-accelerating inflation / restrictive real rates / credit complacent

• Rates: 10yr 4.45% (peaked 4.67 mid-May), move is real-rate led (10yr reals 2.06 vs ~1.90) with 2yr pinned ~4.00 — term-premium bear-steepener, not a cut steepener.
• Fed: funds 3.64%, parked since Jan; data-dependent, CPI still grinding (~6.4% 3m annualized headline).
• Credit/vol: HY OAS 274bps, VIX 15 — complacent, priced for perfection.
• Dollar/oil: broad USD firm ~119.3; oil -4% on month.

Tilt for the board: quality + cash-flow yield over long-duration growth while reals >2% and 10yr >4.30%; keep modest low-vol bias. Energy is the structural inflation hedge but the near-term tape softened. Daniel/Margaret — size sector and names against this, not against the index default.